tbuckley/cabot-search huggingface dataset:
Abstract 14088: Advanced Glycation Endproducts (AGEs) Fluorescence as a Biomarker for Risk of Diabetes Patients
Authors: Fernanda R Paolillo, Audrey Borghi-Silva, Vicente S Mattos, Gabriela Arthuzo, Jarbas C de Castro Neto, Vanderlei S Bagnato
Journal: Circulation (2016)

Introduction:  Advanced glycation endproducts (AGEs) are non-enzimatic glycation of proteins, lipids or nucleic acids formed during normal life. However, the accumulation of accelerated AGEs can occur due to increased oxidative and glycemic stress. This has led to a cross-linking of proteins, mainly collagen from skin. In this context, fluorescent AGEs, such as pentosidine, have been measured by optical techniques. Fluorescence spectroscopy may provide opportunities for diagnosis due to low-cost screening, portability and the possibility of a real-time response using a noninvasive and nondestructive investigative method. Biological tissues contain chromophores that absorb light, as well as fluorophores that absorb and reemit light to help in the initial screening of several diseases, such as diabetes.   Hypothesis:  Fluorescence spectroscopy of skin can identify AGEs in diabetes patients.   Methods:  Ninety four women and men aged 20 to 80 years with or without type 1 or 2 diabetes were evaluated. The fluorescence spectrometer was used to illuminate a skin surface with a peak excitation of 370 nm (ultraviolet A). The right forearm was posited on the device to measure the skin autofluorescence. Three measurements were performed to obtain an average of score. Body mass index (BMI), waist and hip circumferences, body fat percentual, heart rate (HR) and blood pressure (BP) were measured.   Results:  There were prevalence of the 15% for hypertension, 20% for dyslipidemia, 30% for sedentary lifestyle, 53% for social alcohol intake and 100% for non-smokers among people investigated. The AGEs fluorescence score was significantly higher in diabetic patients compared with healthy subjects (3.3±1.0 vs 1.8±0.5, p   Conclusions:  Highly accelerated AGEs are present in diabetic patients, which are considered one of the important pathogenic mechanisms resulting in organ damage and severity of diabetes-related complications. Therefore, fluorescent AGEs in the skin may be a convenient way for noninvasive screening of diabetes and risk of related complications associated with AGEs accumulation.
Brote de rubéola en la comunidad Latino-americana, Madrid, España, Diciembre 2002 - Marzo 2003
Authors: C Lemos, R Ramirez, M Ordobas, D H Guibert, J C Sanz, L Garcia, J. F. Martinez Navarro
Journal: Eurosurveillance (2004)

En Espana la cobertura de vacunacion contra la rubeola es alta. Hasta 1998, en Latino America, 10 a 25% de las mujeres en edad fertil eran susceptibles a la rubeola. Actualmente, 41 (93%) paises latinoamericanos introduciran la vacuna contra la rubeola en sus programas infantiles. La poblacion inmigrante adulta constituyo una bolsa de susceptibles a la infeccion por la rubeola. En Febrero 2003, la vigilancia del Plano de Eliminacion del Sarampion de Madrid, detecto ocho casos de rubeola. La poblacion afectada eran mujeres inmigrantes en edad fertil. 
Para el estudio descriptivo, un caso confirmado era una persona con fiebre y eritema, y una serologia IgM positiva para la rubeola, con inicio entre el 01 Diciembre 2002 y 31 Marzo 2003, residente en Madrid. 
Un total de 19 casos de rubeola fueron identificados, 15 confirmados y 4 probables. Cuatorze (73.7%) casos eran mujeres en edad fertil. La edad media fue 25.1 anos. Un embarazo fue diagnosticado levando a una interrupcion voluntaria. 11 (57.9%) casos eran de Ecuador. La residencia media en Espana fue 41 meses. Ningun caso y 54 (78.3%) contactos familiares no estaban vacunados. La tasa de ataque secundaria en ambito familiar fue de 9% .
Detectamos la difusion de la rubeola en la comunidad Latino-Americana, residente en Madrid, Espana. Las intervenciones propuestas fueron la vacunacion de los inmigrantes adultos, educacion sanitaria sobre la prevencion de la rubeola congenita y la formacion de los profesionales sanitarios sobre el diagnostico y tratamiento de los casos.
Aflibercept in combination with FOLFIRI for the 2nd-line treatment of patients with metastatic colorectal cancer (MCRC): safety data from a single institute experience
Authors: M. Muntoni, M.B. Aloi, D. Capra, E. Defraia, M. Dettori, L. Mascia, A.M. Lanzillo
Journal: Annals of Oncology (2017)
Intensive Blood Pressure Control in Autosomal Dominant Polycystic Kidney Disease—How Safe Is It?
Authors: Mohammadreza Ardalan, Samad E. J. Golzari
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 20708: NLRP3 Inflammasome Inhibits Cholesterol Efflux in Macrophages by Down-Regulating Gpr109a Expression: A Novel Pro-Atherogenic Mechanism
Authors: Shuang Chen, Gantsetseg Tumurkhuu, Jargalsaikhan Dagvadorj, Rebecca A Porritt, Timothy R Crother, Kenichi Shimada, Ebru Erbay, Moshe Arditi
Journal: Circulation (2017)

Introduction: Recent studies suggest that Nlrp3 inflammasome activation plays a critical role in the development of atherosclerosis and Chlamydia pneumoniae (Cpn) infection has been shown to accele...
MA 06.04 Development of Next-Generation Sequencing Based Cancer Panel and Its Clinical Implications in Lung Cancer
Authors: Y. Hwang, K. Hyun, S. Im, N. Kwon, Y.J. Jung, S.B. Lee, Y.H. Kim, S. Park, H.J. Lee, I.K. Park, C.H. Kang, Y. Kim
Journal: Journal of Thoracic Oncology (2017)
NCOG-13. TOWARDS LONG-TERM MEMORY MAPPING DURING AWAKE CRANIOTOMY: VALIDATION OF A SHORT-FORMAT TASK IN PATIENTS WITH BRAIN TUMORS
Authors: Kelsey Bowman, Olivia Bjorkquist, Donna Bridge, Joel Voss, Matthew Tate
Journal: Neuro-Oncology (2017)

Patients with brain tumors often suffer from memory impairment, a symptom that results in a significant decrement to quality of life. However, unlike sensorimotor and language functions, memory is not mapped during awake craniotomies. Following on research showing that long-term memory processes are operative and can be measured over compact timescales, our goal is to develop a brief probe of memory function that will be suitable for the confines of the OR environment. Here, we report a validation study of a candidate task. We designed a novel memory test in which patients studied collections of five objects arranged in a circle. After a 4s unfilled delay, the locations of two objects were swapped and patients attempted to identify these swaps. To vary difficulty, objects included either abstract squiggles or identifiable shapes. Fifty-five patients with supratentorial parenchymal tumors completed a series of standardized neuropsychological tests (including classical memory measures), as well our novel task. Neuropsychological battery performance was compared to performance on the novel paradigm using across-subject correlation analysis. 46/55 patients completed all components of the study. Performance on the squiggle version of the task was strongly correlated with total recall on the standardized battery (r=0.586, p<0.0001), whereas the object version correlated with a variety of domains, including total recall (r=0.4267, p=0.0031), visuospatial (r=0.560, p<0.0001), language (r=0.485, p=0.0006), and attention (r=0.477, p=0.0008). An analysis using moving averages across sequential trials indicated that only four squiggle trials were necessary to obtain a stable estimate of an individual’s overall performance, and as low as a single trial for the objects. Our novel test provides a practical way to map both long-term memory (squiggles) and global cognition (objects) with low trial numbers, making intraoperative testing during awake craniotomy feasible, and may allow for more reliable preservation of cognition postoperatively.
EPID-16. HEREDITARY BRAIN TUMORS ARE MORE COMMON THAN YOU THINK: GERMLINE MUTATIONS IN BENIGN AND MALIGNANT PRIMARY BRAIN TUMORS
Authors: Michelle Jackson, Holly LaDuca, Amanda Bergner
Journal: Neuro-Oncology (2017)

As genetic testing technology has evolved, the landscape of hereditary brain tumors is expanding beyond syndromes such as Li-Fraumeni, von-Hippel-Lindau, neurofibromatosis, and tuberous sclerosis. Anecdotally, many consider benign brain tumors to have less of a germline component than malignant tumors. Based on published literature, it is unclear if there are differences between benign and malignant tumors in terms of the germline contribution to causation and this study examines that gap. All sequential cases with at least one diagnosis of a primary brain tumor (PBT) submitted to a single laboratory for hereditary cancer multigene panels between March 2012 and December 2016 were retrospectively reviewed. Cases were grouped as benign or malignant/malignant potential based on the reported pathology. Age at diagnosis and genetic testing, and mutation distribution were analyzed. Of 610 PBT cases, about half (51.8%) were benign. Germline mutations were identified in 14.2% (n=316) of benign cases and 17.4% (n=294) of malignant cases. Overall, 62.1% had multiple primary tumors; 75.3% in the benign subgroup had >1 primary cancer diagnosis compared to 48.0% in the malignant group. In the benign subgroup, 53.3% had their PBT as the initial or concurrent diagnosis compared to 61.0% in the malignant subgroup. The average length of time from PBT diagnosis to genetic testing was similar for benign and malignant subgroups (9y and 8y, respectively). Though this cohort was enriched for patients with multiple primary cancer diagnoses, germline mutations were frequent among both benign and malignant subgroups. In the malignant subgroup, over half presented with a PBT as their first diagnosis, however, genetic testing was delayed for close to a decade on average. Clinician awareness of germline genetic findings among both benign and malignant PBT cases, and the utilization of genetic testing to assist with appropriate and comprehensive screening are important.
ACTR-21. UPDATED RESULTS OF A PHASE I DOSE-ESCALATION, DOSE-EXPANSION STUDY OF DISULFIRAM AND ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Jiayi Huang, Jian Campian, Amit Gujar, Christina Tsien, George Ansstas, David Tran, Todd Dewees, Albert Kim, A Craig Lockhart
Journal: Neuro-Oncology (2017)

Disulfiram has promising preclinical activity against glioblastoma (GBM) as well as synergy with temozolomide. In a phase I study for newly diagnosed GBM after chemoradiotherapy, we have previously shown the maximum tolerated dose (MTD) of disulfiram with adjuvant temozolomide is 500mg per day (QD). Here we report the updated results of the phase I study with a dose-expansion cohort with the addition of concurrent copper gluconate supplement. The phase I study consisted of an initial dose-escalation phase of disulfiram 500-1000mg QD during adjuvant temozolomide, followed by a dose-expansion phase of disulfiram 500mg QD with concurrent copper 2mg three times daily (TID) during adjuvant temozolomide. Progression-free survival (PFS) and overall survival (OS) were determined from the start of adjuvant temozolomide/disulfiram. A total of 18 patients were enrolled: 7 patients received 500mg disulfiram, 5 patients received 1000mg disulfiram, and 6 patients received 500mg disulfiram with copper. At 1000mg disulfiram, 4 patients (80%) required dose discontinuation or reduction within the first month due to toxicity. At 500mg disulfiram, 1 patient (8%) required dose reduction during the first month, and 1 patients (8%) required dose discontinuation due to toxicity after 2.6 months. Addition of copper to disulfiram did not increase toxicity. Dose-limiting toxicities (DLTs) included delirium, motor neuropathy, ataxia, and nausea/diarrhea. After a median follow-up of 12.0 months, 16 patients have progressed, and 11 patients have died. Median PFS was 4.5 months (95% CI: 0.8–8.2), and 1-year PFS was 14% (95% CI: 0–30%). Median OS was 13.9 months (95% CI: 1.9–25.9), and 2-year OS was 28% (95% CI: 3–54%). The MTD of disulfiram at 500mg per day and copper 2mg TID can be safely combined with adjuvant temozolomide. A multi-institutional phase II study evaluating addition of disulfiram/copper to temozolomide for recurrent temozolomide-resistant GBM is ongoing (NCT03034135).
P1.02-060 Podoplanin Expression in Cancer-Associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung
Authors: Y. Yurugi, W. Fujiwara, Y. Kidokoro, K. Hosoya, T. Ohno, T. Sakabe, Y. Kubouchi, M. Wakahara, Y. Takagi, T. Haruki, K. Nosaka, K. Miwa, K. Araki, Y. Taniguchi, T. Shiomi, H. Nakamura, Y. Umekita
Journal: Journal of Thoracic Oncology (2017)
Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study
Authors: V. Adamo, G. Ricciardi, S. Schifano, A. Russo, V. Gebbia, L. Blasi, D. Giuffrida, G. Scandurra, A. Savarino, A. Butera, N. Borsellino, F. Verderame, M. Caruso
Journal: Annals of Oncology (2017)
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study
Authors: Sengwee Toh, Marsha E. Reichman, David J. Graham, Christian Hampp, Rongmei Zhang, Melissa G. Butler, Aarthi Iyer, Malcolm Rucker, Madelyn Pimentel, Jack Hamilton, Samuel Lendle, Bruce H. Fireman, Gwyn Saylor, Neesha Nathwani, Susan E. Andrade, Jeffrey S Brown, Denise M. Boudreau, Robert T. Greenlee, Marie R. Griffin, Michael A. Horberg, Nancy D. Lin, Cheryl N. McMahill-Walraven, Vinit P. Nair, Pamala A. Pawloski, Marsha A. Raebel, Nandini Selvam, Connie Mah Trinacty
Journal: Diabetes Care (2017)

The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. We prospectively examined the association between saxagliptin use and acute myocardial infarction (AMI).We identified patients aged ≥18 years, starting from the approval date of saxagliptin in 2009 and continuing through August 2014, using data from 18 Mini-Sentinel data partners. We conducted seven sequential assessments comparing saxagliptin separately with sitagliptin, pioglitazone, second-generation sulfonylureas, and long-acting insulin, using disease risk score (DRS) stratification and propensity score (PS) matching to adjust for potential confounders. Sequential testing kept the overall chance of a false-positive signal below 0.05 (one-sided) for each pairwise comparison.We identified 82,264 saxagliptin users and more than 1.5 times as many users of each comparator. At the end of surveillance, the DRS-stratified hazard ratios (HRs) (95% CI) were 1.08 (0.90-1.28) in the comparison with sitagliptin, 1.11 (0.87-1.42) with pioglitazone, 0.79 (0.64-0.98) with sulfonylureas, and 0.57 (0.46-0.70) with long-acting insulin. The corresponding PS-matched HRs were similar. Only one interim analysis of 168 analyses met criteria for a safety signal: the PS-matched saxagliptin-pioglitazone comparison from the fifth sequential analysis, which yielded an HR of 1.63 (1.12-2.37). This association diminished in subsequent analyses.We did not find a higher AMI risk in saxagliptin users compared with users of other selected antihyperglycemic agents during the first 5 years after U.S. Food and Drug Administration approval of the drug.
OA 10.05 Non-Invasive Molecular Profiling in NSCLC by Targeted and Whole Exome Analysis of Plasma cfDNA
Authors: M. Cheng, J. Yang, M. Shady, P. Ulz, E. Heitzer, N. Socci, V. Seshan, M. Offin, D. Stephens, A. Makhnin, N. Tandon, S. Datta, D. Selcuklu, K. Huberman, K. Vanness, E. Gedvilaite, A. Viale, M. Arcila, M. Ladanyi, J. Chaft, C. Rudin, M. Berger, D. Solit, B. Li, D. Tsui
Journal: Journal of Thoracic Oncology (2017)
Proton Beam Therapy for Iris Melanomas in 107 Patients
Authors: Juliette Thariat, Ahmed Rahmi, Julia Salleron, Carlo Mosci, Benjamin Butet, Celia Maschi, Francesco Lanza, Sara Lanteri, Stephanie Baillif, Joel Herault, Thibaud Mathis, Jean Pierre Caujolle
Journal: Ophthalmology (2017)
P1.02-055 Genotyping Squamous Cell Lung Carcinoma Among Hispanics (Geno1.1-CLICaP)
Authors: A. Cardona, O. Arrieta, L. Rojas, Z. Zatarain-Barron, L. Corrales, C. Martin, J. Rodriguez, J. Rodriguez, P. Archila, A. Ruiz-Patiño, R. Rosell
Journal: Journal of Thoracic Oncology (2017)
EXTH-57. HIGH CONTENT SCREENING OF PATIENT-DERIVED CELL LINES HIGHLIGHTS THE POTENTIAL OF NON-STANDARD CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA
Authors: Jessica Taylor, Kenny Yu, Omar Pathmanaban, Deniz Beyit, Joanna Dutko-Gwozdz, Rod Benson, Gareth Griffiths, Brian Telfer, Kaye Williams, Ian Peers, Peter Ceuppens, Catherine McBain, Ian Kamaly-Asl, Brian Bigger
Journal: Neuro-Oncology (2017)

Glioblastoma Multiforme (GBM) is the most common primary brain tumor in adults, yet survival outcomes remain poor. First line treatment is well established but with disease recurrence almost inevitable, improving prognosis is challenging. With the aim of personalising therapy at recurrence we have established a high content screening (HCS) platform to analyse the sensitivity profile of seven patient-derived cancer stem cell lines to 82 FDA-approved chemotherapy drugs, with and without irradiation. Seven cancer stem cell lines were derived from patients with GBM, or GBM variants. Along with the established cell line U87-MG, each patient-derived line was cultured in tandem in serum-free conditions as adherent monolayers and three-dimensional neurospheres. Chemotherapeutics were screened at multiple concentrations and cells double-stained to observe their effect on both cell death and proliferation. Sensitivity was classified using high-throughput algorithmic image analysis. Cell line specific drug responses were observed across the seven patient-derived cell lines. Few agents were seen to have radio-sensitising effects, yet some drug classes showed a marked difference in efficacy between monolayers and neurospheres. In vivo validation of six drugs in a U87 subcutaneous flank model indicated that a three-dimensional culture scenario more effectively predicts chemosensitivity of patient-derived GBM lines. Mitoxantrone, a type II topoisomerase inhibitor, was the most successful drug tested, inhibiting tumor growth by an average of 86.69% when compared to control (p = <0.0001). Bortezomib and Actinomycin D also significantly inhibited growth by 69.63% and 60.37% respectively (p = <0.0001). The study puts forward a number of non-standard chemotherapeutics that could be useful in the treatment of recurrent GBM, whilst demonstrating the potential of HCS to be used for personalised treatment based on the chemosensitivity profile of patient tumor cells.
P3.04-002 A Randomized Phase II Study of Carboplatin plus Nab-Paclitaxel with or Without Nintedanib for NSCLC with IPF (J-SONIC): Trial in Progress
Authors: K. Otsubo, J. Kishimoto, H. Kenmotsu, Y. Minegishi, E. Ichihara, A. Shiraki, T. Kato, S. Atagi, H. Horinouchi, M. Ando, Y. Kondoh, M. Kusumoto, K. Ichikado, N. Yamamoto, Y. Nakanishi, I. Okamoto
Journal: Journal of Thoracic Oncology (2017)
PDCT-03. PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN PEDIATRIC BRAIN TUMORS
Authors: Stewart Goldman, Mark Kieran, Sabine Mueller, Jill Buck, Richard MacKenna, John Barrett, Laurence Cooper, Francois Lebel
Journal: Neuro-Oncology (2017)

Pediatric glioblastoma has an aggressive clinical course accounting for significant morbidity and mortality among children with brain tumors. Only 10% of children with DIPG survive for 2 years following diagnosis, and less than 1% survive for 5 years. The median survival is 9 months from diagnosis. New therapies are urgently needed. Ad-RTS-hIL-12 is a novel gene therapy expressing IL-12 under the control of an oral activator ligand, veledimex, via the RheoSwitch Therapeutic System® gene switch. Intratumoral administration of Ad-RTS-hIL-12 results in targeted tumor cytotoxicity and induction of systemic T-cell memory. Ad-RTS-hIL-12 + veledimex is a treatment strategy to extend the IL-12 therapeutic window. Based on encouraging data from an ongoing phase I dose escalation trial in adults with recurrent/progressive glioma and preclinical data in a GL-261 medullary glioma mouse model, we expect significant safety margins and tolerability profile in pediatric glioma. In a phase 1 adult study, subjects received intratumoral injections of Ad-RTS-hIL-12 2x1011 viral particles during resection or administered stereotactically. Daily oral veledimex began prior to surgery or following stereotactic injection. Overall, Ad-RTS-hIL-12 + veledimex in adults was well tolerated; toxicities were predictable and reversible upon discontinuing veledimex with a correlation between veledimex dose, BBB penetration and drug related AEs. The tolerability and encouraging survival observed warrants a dose escalation pediatric trial for subjects with recurrent/progressive brain tumors. Two groups of subjects receiving Ad-RTS-hIL-12 2x1011 viral particles are planned: Arm 1 receives Ad-RTS-hIL-12 intratumorally after resection of supratentorial tumors that are unresponsive to conventional treatment or for which there is no alternative curative therapy; Arm 2 consists of stereotactic injection in subjects with DIPG post prior standard focal radiotherapy and for which a diagnostic biopsy has previously been obtained. Subjects receive BSA adjusted escalating doses of 10 or 20mg veledimex. An update will be presented.
P1.03-028 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Untreated Stage IV Squamous Cell Lung Cancers
Authors: P. Paik, A. Srikakulum, L. Ahn, A. Plodkowski, K. Ng, D. Mcfarland, J. Fiore, A. Iqbal, J. Eng, M. Kris, C. Rudin
Journal: Journal of Thoracic Oncology (2017)